This “End-Stage Renal Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in End-Stage Renal Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
End-Stage Renal Disease Understanding
End-Stage Renal Disease (ESRD) is the last stage that is stage five of chronic kidney disease (CKD). ESRD typically occurs when chronic kidney failure has progressed to the point that kidney function is less than 10% of capacity. As chronic kidney disease progresses to end-stage renal disease, signs and symptoms include: nausea, vomiting, uremia, fatigue and weakness, abnormal thyroid levels, muscle twitches and cramps, swelling of feet and ankles, persistent itching, chest pain, shortness of breath, and high blood pressure. The major risk factors associated with CKD are age, gender, race and ethnicity, family history, drug use, smoking, and socioeconomic status; and concurrent diseases, such as hypertension and diabetes. Diagnosis is primarily based on a detailed medical history, clinical examination and laboratory tests. Renal scans can give sufficient information about the anatomy and function of kidneys. The only treatments available for ESRD is kidney transplant or dialysis. Emerging drugs are currently under clinical developmental studies to prevent serious complications of ESRD.
"End-Stage Renal Disease - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the End-Stage Renal Disease pipeline landscape is provided which includes the disease overview and End-Stage Renal Disease treatment guidelines. The assessment part of the report embraces, in depth End-Stage Renal Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, End-Stage Renal Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence End-Stage Renal Disease R&D. The therapies under development are focused on novel approaches to treat/improve End-Stage Renal Disease.
This segment of the End-Stage Renal Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TX 200 is a chimeric antigen receptor, engineered regulatory T cell (CAR-Treg) based HLA-A2-targeted autologous gene therapy. The drug is in Phase I/II clinical development for the prevention of immune-mediated rejection following HLA-A2 mismatched kidney transplantation for end-stage renal disease (ESRD).
Desidustat is a novel, oral, small molecule based hypoxia-inducible factor prolyl hydroxylase (HIFPH) inhibitor. The drug is in Phase III clinical development studies for the treatment of anaemia in patients suffering from Chronic Kidney Disease (CKD) and completed Phase II clinical studies for COVID 2019 infections.
This segment of the report provides insights about the different End-Stage Renal Disease drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 25+ key companies which are developing the therapies for End-Stage Renal Disease. The companies which have their End-Stage Renal Disease drug candidates in the most advanced stage, i.e. Phase III include, Zydus Cadila.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses End-Stage Renal Disease therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging End-Stage Renal Disease drugs.
Current Treatment Scenario and Emerging Therapies:
This product will be delivered within 1-3 business days.
Geography Covered
- Global coverage
End-Stage Renal Disease Understanding
End-Stage Renal Disease: Overview
End-Stage Renal Disease (ESRD) is the last stage that is stage five of chronic kidney disease (CKD). ESRD typically occurs when chronic kidney failure has progressed to the point that kidney function is less than 10% of capacity. As chronic kidney disease progresses to end-stage renal disease, signs and symptoms include: nausea, vomiting, uremia, fatigue and weakness, abnormal thyroid levels, muscle twitches and cramps, swelling of feet and ankles, persistent itching, chest pain, shortness of breath, and high blood pressure. The major risk factors associated with CKD are age, gender, race and ethnicity, family history, drug use, smoking, and socioeconomic status; and concurrent diseases, such as hypertension and diabetes. Diagnosis is primarily based on a detailed medical history, clinical examination and laboratory tests. Renal scans can give sufficient information about the anatomy and function of kidneys. The only treatments available for ESRD is kidney transplant or dialysis. Emerging drugs are currently under clinical developmental studies to prevent serious complications of ESRD.
"End-Stage Renal Disease - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the End-Stage Renal Disease pipeline landscape is provided which includes the disease overview and End-Stage Renal Disease treatment guidelines. The assessment part of the report embraces, in depth End-Stage Renal Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, End-Stage Renal Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence End-Stage Renal Disease R&D. The therapies under development are focused on novel approaches to treat/improve End-Stage Renal Disease.
End-Stage Renal Disease Emerging Drugs Chapters
This segment of the End-Stage Renal Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
End-Stage Renal Disease Emerging Drugs
TX 200: Sangamo Therapeutics
TX 200 is a chimeric antigen receptor, engineered regulatory T cell (CAR-Treg) based HLA-A2-targeted autologous gene therapy. The drug is in Phase I/II clinical development for the prevention of immune-mediated rejection following HLA-A2 mismatched kidney transplantation for end-stage renal disease (ESRD).
Desidustat: Zydus Cadila
Desidustat is a novel, oral, small molecule based hypoxia-inducible factor prolyl hydroxylase (HIFPH) inhibitor. The drug is in Phase III clinical development studies for the treatment of anaemia in patients suffering from Chronic Kidney Disease (CKD) and completed Phase II clinical studies for COVID 2019 infections.
End-Stage Renal Disease: Therapeutic Assessment
This segment of the report provides insights about the different End-Stage Renal Disease drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in End-Stage Renal Disease
There are approx. 25+ key companies which are developing the therapies for End-Stage Renal Disease. The companies which have their End-Stage Renal Disease drug candidates in the most advanced stage, i.e. Phase III include, Zydus Cadila.
Phases
This report covers around 25+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
End-Stage Renal Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
End-Stage Renal Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses End-Stage Renal Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging End-Stage Renal Disease drugs.
End-Stage Renal Disease Report Insights
- End-Stage Renal Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
End-Stage Renal Disease Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing End-Stage Renal Disease drugs?
- How many End-Stage Renal Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of End-Stage Renal Disease?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the End-Stage Renal Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for End-Stage Renal Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Sanifit
- Merck Sharp & Dohme Corp.
- Shengzhen Sciprogen Bio-pharmaceutical (3SBio)
- Zydus Cadila
- Humacyte
- Iperboreal Pharma
- Aronora
- Ionis Pharmaceuticals
- Novo Nordisk
- Unicycive Therapeutics
- Sangamo Therapeutics
- AstraZeneca
Key Products
- SNF472
- MK-2060
- RD001
- Desidustat
- Human Acellular Vessel (HAV)
- XyloCore
- AB002
- ISIS 416858
- Ziltivekimab
- UNI-494
- TX 200
- Dapagliflozin
This product will be delivered within 1-3 business days.
Table of Contents
IntroductionExecutive Summary
End-Stage Renal Disease: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
End-Stage Renal Disease - Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
Desidustat: Zydus Cadila
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
RD001: Shengzhen Sciprogen Bio-pharmaceutical (3SBio)
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I/II)
- Comparative Analysis
TX 200: Sangamo Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Preclinical/Discovery Stage Products
- Comparative Analysis
UNI-494: Unicycive Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
End-Stage Renal Disease Key Companies
End-Stage Renal Disease Key Products
End-Stage Renal Disease- Unmet Needs
End-Stage Renal Disease- Market Drivers and Barriers
End-Stage Renal Disease- Future Perspectives and Conclusion
End-Stage Renal Disease Analyst Views
AppendixList of Tables
Table 1 Total Products for End-Stage Renal Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for End-Stage Renal Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Sanifit
- Merck Sharp & Dohme Corp.
- Shengzhen Sciprogen Bio-pharmaceutical (3SBio)
- Zydus Cadila
- Humacyte
- Iperboreal Pharma
- Aronora
- Ionis Pharmaceuticals
- Novo Nordisk
- Unicycive Therapeutics
- Sangamo Therapeutics
- AstraZeneca
